ADVM May 2024 7.000 put
| Previous close | 0.1500 |
| Open | 0.1000 |
| Bid | 0.0000 |
| Ask | 0.3000 |
| Strike | 7.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.1000 - 0.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 51 |
GlobeNewswireAdverum Biotechnologies to Participate in Upcoming May Investor Conferences
REDWOOD CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the following upcoming investor conferences: 2024 RBC Global Healthcare Conference on Tuesday, May 14, 2024 at 4:05 p.m. ET.BofA Securities 2024 Health Care Conference on Wednesday, May 16, 2024 at 3:40 p.m. PT.H.C. Wainwright
ZacksAdverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Adverum Biotechnologies (ADVM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present the 26-week landmark interim analysis from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) at the American Society of Retina Specialists (
